GlassScriptPhysician profile
Vel Natesan
NPI 1457372310
$3,971.54
in general payments reported to CMS, 2019-2025
30 companies · $908 in 2025
The $908 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $222 · 2021: $99.00 · 2022: $462 · 2023: $521 · 2024: $938 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $599.68 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $511.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $354.17 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $325.90 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $291.31 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $196.84 | 2019-2025 | |
| Pfizer INC. | $181.97 | 2019-2025 | |
| Abbvie INC. | $159.95 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $142.72 | 2019-2024 | Gardasil 9, Verquvo, Capvaxive |
| Sumitomo Pharma America, INC. | $136.43 | 2023-2025 | Gemtesa |
| Scpharmaceuticals INC. | $107.55 | 2024-2025 | |
| Dexcom, INC. | $101.21 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $92.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.92 | 2019-2025 | Jardiance, Tradjenta |
| Allergan, INC. | $89.05 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $73.92 | 2019-2025 | Eliquis, Camzyos |
| Kowa Pharmaceuticals America, INC. | $66.18 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.67 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $60.38 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $56.46 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $45.18 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $36.35 | 2019-2020 | |
| Astellas Pharma US INC | $35.45 | 2019-2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $31.89 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $29.32 | 2024 | |
| Boston Scientific Corporation | $27.33 | 2025 | Ams 700 |
| Horizon Therapeutics Plc | $22.74 | 2022 | |
| Shire North American Group INC | $14.82 | 2019 | |
| Soleno Therapeutics, INC. | $14.81 | 2025 | Vykat Xr |
| Teva Pharmaceuticals USA, INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vel Natesan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.